The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. "With skyrocketing prescription drug price increases presenting hospitals, health systems and patients with remarkable challenges, the 340B program is as critical as ever in helping provide access to health care services for vulnerable patients and communities,” said AHA Executive Vice President Tom Nickels. “The 340B ceiling price and civil monetary penalties rule were intended to shine needed light on drug manufacturer price increases and hold drug manufacturers accountable for price overcharging. These reasons are why we continue to be disappointed in the delays – including five times since the beginning of last year alone – of the final rule and in the short shrift given to the review of the latest public comments. The irony is not lost on us that drug manufacturers continue to lobby for increased reporting for hospitals and others while refusing any transparency on their part."

Related News Articles

Headline
The AHA today unveiled a set of principles to he
Insights and Analysis
Harney District Hospital, Burns, Ore., is one of many hospitals nationwide that have embraced the Lean mentality, modeled after Toyota’s discipline of lean…
Headline
National hospital organizations, including the AHA, today urged congressional leaders to delay the start of the Medicaid disproportionate share hospital cuts…
Headline
The AHA today urged the Centers for Medicare…
Headline
Commenting today on the Centers for Medicare…
Headline
The AHA Friday shared recommendations for developing a unified post-acute care prospective payment system as required by the Improving Medicare Post-Acute Care…